Am on another close knit board but many there are more

New Post Public Reply Private Reply Replies (4) Message Board
petemantx
539
Am on another close knit board but many there are more traders than investors. As one would imagine, they are going berserk over the rapid drop in price over the last month or so. I answered them below, trying to allay some of their fears and trying to make them realize what they have in an IPIX investment:


Investors know what they own, traders only know what they see on a chart. Investors know what the company has said in regards to when they will announce deals, traders want action today regardless of the process needed to attain large returns (same problem most companies have today in worrying about quarterly returns instead of long term growth and profitability). IPIX was in the .70s a mere month or two ago. What has changed for this rapid drop? Negative news? No. Competitor products being approved that diminishes the chances for our products to succeed? No, just the opposite. Has mgt quit communicating with shareholders due to dire circumstances? No, just the opposite, in talks with BPs as to deals as evidenced by CDAs.

If you don't believe Brilacidin has already established itself as a billion dollar drug that could rival Humira down the line in annual sales, being an antibiotic/anti-inflammatory and a probable large dermatology related success then sell and chase your pennies in other stocks you can trade daily. We know we are but days to a couple of weeks away from Prurisol P2b results that could (and I believe should) result in Prurisol becoming the leading treatment for psoriasis, but if you can't handle the short wait then IPIX is not for you. Biotech doesn't work on a fast track. If you don't believe the hundred Billion $+ reserves of BPs are looking for a pipeline in which to invest and cannot see that IPIX has the most astounding lineup of 3 drugs already thru P2 trials, then IPIX is not for you. If you are jumping with joy at a gain of a price share rise to $3/share and cannot wait a matter of a month or two for a possibility of 10X that then IPIX is not for you. Play your charts, make your pennies, and be happy. Is success guaranteed? No. But look at what is in our favor. 5 trials with no failures and NO SAFETY ISSUES. Does eveyone understand the value in that for a pipeline of drugs that should work in a revenue stream of $100B/ yr? In the realm of biotech that is nearly beyond belief and is worth an immeasurable amount. To put it in perspective, how much revenue a yr is NXO going to get from the camera for iphones and such? Would most be happy w/ $1Billion/yr? Brilacidin has as it's smallest target Oral Mucositis and that alone should reach that level. Add in IBD (Irritable Bowel Disorders) and you get maybe an additional $10-15B, add in dermatology apps and another possible $20B, add in antibiotic uses at another number of Billions, then Prurisol just for psoriasis possible $5-8B/yr and the rest of the anti-immune diseases (there are about 100 of them) many billions and we haven't even mentioned Kevetrin that has achieved being able to energize the pathway to ignite the p53 gene (the Guardian Angel Gene) and the most researched subject in medical history. The top cancer drugs did about $90 billion / yr and K could become a combo drug for all or most of them. I'd say IPIX odds are very high in becoming a very successful company, but if you can't stand some heat sell and get back in after the deals are actually signed. As it is now, though, most sound like they have bought the paid trolls garbage of no science, no mgt, no opportunities, et al and it sickens me to see so many buying their rot. There are very, very few true golden rings to grab in the field of investing. IPIX is one, so obstacles are to be expected and risks taken. That is why there is such a large operation in place to try and undermine them at this point in time , because the shorts know their time of ruling the share price is about to come to an end.

The company's latest PR was about selecting German based EVONIK as the contractor to make our Brilacidin sachets for Oral Mucositis and this will be the exact formulation that we will bring to market. Ergo, we have solved the formulation for the sachet. Who is EVONIK? 38K employees operating in over 100 countries with yearly revenues of about 14B Euros per year. They have a major Investing arm and they will be able to provide IPIX with gels/foams/creams/pills/IV solutions. Could we be discussing a partnership with them so that we two also distribute the OM sachet worldwide and keep this $1B+ revenue stream to ourselves? The revenue stream should actually rise significantly as rather than just for head and neck cancers, this product will be so easy to administer and be so universally effective that all patients being treated with radiation/chemo will be prescribed it as no oncologist will want to get hit with a lawsuit should their patient get OM and they didn't prescribe this easy fix for the problem ever occurring. This is just one of many scenarios that could be playing out. Again, it doesn't happen overnight, but EVONIK doesn't get in bed with companies that they don't see having a good future.

Maybe we don't partner with EVONIK for worldwide distribution, but in negotiating with BPs Leo could sure use this possibility as a leverage point as to why BP better step to the plate with an acceptable offer. We aren't going into these negotiations with an empty pistol. We are negotiating from a position of strength.

I am not trying to say IPIX is a given success, I am only trying to stress why it should be viewed with a different set of eyes than a normal stock which has only millions to hundreds of millions in possible revenues.

Just for those needing a refresher, Dr Bertolino was head of dermatoloy for both Pfizer and Novartis and his contacts and expertise in this field should be of immense value for selling Brilicidin for dermatology applications (Eczema, acne, and Hidradenitis Suppurativa) which have yearly revenues over $40B.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 60

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 0

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 85

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 34

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 16

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 76

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 33

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 54

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 15

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Alert: Join Class Action Against Vestis Corporation

Updated Category News Views 240

Important Notice for Investors in Vestis Corporation Levi & Korsinsky, LLP is reaching out to those who have invested in Vestis Corporation (NYSE: VSTS) regarding a significant class action securities lawsuit. This initiative is intended for individuals who believe they faced losses as a consequence of the alleged securities fraud involving the company. Understanding the...

Continue Reading
Wegovy's Impact on MASH Care: Insights into Physician Adoption

Updated Category News Views 168

Wegovy's Revolutionary Role in MASH Treatment Wegovy, known in the medical community as semaglutide 2.4mg, has recently garnered approval as a treatment for metabolic dysfunction-associated steatohepatitis (MASH). This development is viewed as a crucial advancement for a condition that affects a substantial patient population. With significant unmet needs, the...

Continue Reading
Opportunity for Orthofix Investors to Join Class Action Lawsuit

Updated Category News Views 248

Class Action Lawsuit Opportunity for Orthofix Investors Investors in Orthofix Medical Inc. have been alerted to a significant opportunity. A class action lawsuit is underway against Orthofix, involving allegations against current and former officers for violations of federal securities laws. If you are among those who encountered substantial losses due to the handling of...

Continue Reading
Meta Strengthens AI Infrastructure with Rivos Acquisition

Updated Category News Views 252

Meta Platforms Aims for AI Dominance Meta Platforms (NASDAQ:META) is making significant strides in the realm of artificial intelligence, channeling resources into massive chip investments and potential acquisitions to bolster its infrastructure. As one of the giants in U.S. technology, Meta is set on further establishing its presence in AI technology with a commitment of...

Continue Reading
Renovating Older Homes? Structural Insight is Key

Updated Category News Views 28

Unearthing the Bones of Older Homes It ain't rocket science to realize that before you swing a sledgehammer in an old house, you’d better know what you’re dealing with. The walls might look like just a bunch of paint and plaster, but underneath, they tell stories older than most of us. It's all laid out in this HelloNation chat with Jason Marks from Ward Construction....

Continue Reading